FDA Guidance and Notices, December 2025: Final Guidance on Real-World Evidence for Devices and QMSR Technical Amendments
For device regulatory teams, the December 2025 document to read first is FDA's final guidance on using real-world evidence (RWE) to support regulatory decisions on medical devices, issued on the 18th. Earlier in the month FDA issued final guidance on the eCopy program for device submissions, and on December 4 it published technical amendments that bring related regulations in line with the Quality Management System Regulation (QMSR). They add nothing new and take effect February 2, 2026.
On the digital health side, a December 8 notice announced TEMPO (Technology-Enabled Meaningful Patient Outcomes), a pilot that works alongside the ACCESS Model of the Centers for Medicare & Medicaid Services (CMS). On December 29, FDA published a petition seeking a conditional 510(k) exemption for radiology software that helps with detection, diagnosis and triage, with comments due February 27, 2026.
Final guidance
- eCopy Program for Medical Device Submissions (December 3): Walks through how to prepare an eCopy of a device submission and send it to FDA.
- Investigator Responsibilities – Safety Reporting for Investigational Drugs and Devices (December 15): Spells out what investigators are responsible for in safety reporting for trials of investigational drugs and devices.
- Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices (December 18): Describes how real-world evidence can be used to support FDA's regulatory decisions on devices.
- Processes and Practices Applicable to Bioresearch Monitoring Inspections (December 19): Lays out the processes and practices FDA follows in bioresearch monitoring inspections.
Draft guidance
- Study of Sex Differences in the Clinical Evaluation of Medical Products (December 15): Covers how sex differences should be studied in clinical evaluation; devices are within its scope.
In the Federal Register
- Medical Devices; Quality Management System Regulation Technical Amendments (December 4): Updates cross-references and terminology in related regulations so they match the QMSR. Nothing new is required, and the changes take effect February 2, 2026.
- Technology-Enabled Meaningful Patient Outcomes (TEMPO) for Digital Health Devices Pilot (December 8): Linked to the CMS ACCESS Model, the pilot supports real-world data collection and future marketing submissions for eligible digital health devices. FDA may consider enforcement discretion on certain requirements device by device, but taking part is not FDA approval or clearance.
- Medical Devices; Exemption From Premarket Notification: Radiology Computer-Aided Detection and/or Diagnosis Devices and Computer-Aided Triage and Notification Devices (December 29): A petition to exempt, with conditions, radiology computer-aided detection and/or diagnosis devices and computer-aided triage and notification devices from 510(k). Comments were invited through February 27, 2026; no exemption had been granted at this stage.
Device classification rules
Most of these write a classification decided earlier into the regulations; they do not mean any individual product was authorized that day. "Reclassification" changes a device type's class, and "proposed" marks a proposed rule open for comment.
Safety communications and other updates
- Total Product Lifecycle Advisory Program (TAP) Pilot Assessment (December 9): An independent look at the Total Product Lifecycle Advisory Program (TAP) pilot, including the early and repeated interaction with FDA that it offers.
Also this month
- December 10: A CDRH webinar used polytetrafluoroethylene (PTFE) as a case study in material substitutions for devices subject to 510(k).
- December 16: FDA held a webinar on key takeaways from the QMSR.
Note: dates are FDA issue dates or Federal Register publication dates. Linked pages may now show a later version.
RA Craft Database is an independent service and is not affiliated with or endorsed by the U.S. FDA. Articles are for general information on product development and regulatory research; they are not legal or regulatory advice for a specific device. Official FDA documents remain the authoritative source.
← All articles